Activity Overview | Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches, a satellite symposium to be held at the 2011 Society for Neuro-Oncology Annual Meeting, will discuss emerging data and provide updates on current standards of care that are relevant to clinicians who provide care to patients with glioblastoma. The scientific agenda has been developed based on educational needs identified in this area of oncology, and will feature didactic lectures and interactive case-based panel discussions to provide participants with valuable insights into the multidisciplinary management of difficult clinical scenarios. |
 Agenda |
| 5.00 PM |
|
Registration and reception
|
| 5.30 PM |
|
Welcome and introduction
Michael Prados, MD
|
| 5.35 PM |
|
Clinical opinion poll
Michael Prados, MD
|
| 5.40 PM |
|
Applying our understanding of glioblastoma tumor biology to diagnosis and treatment
Wolfgang Wick, MD, PhD
|
| 6.00 PM |
|
The impact of new data on optimizing the standards of care in newly diagnosed glioblastoma
Minesh P. Mehta, MD
|
| 6.20 PM |
|
Interactive clinical scenario discussion: Treatment considerations for a patient with newly diagnosed glioblastoma
Moderator: Michael Prados, MD
Panelists: Timothy Cloughesy, MD; Minesh P. Mehta, MD; Wolfgang Wick, MD, PhD
|
| 6.35 PM |
|
Examining novel approaches for the management of recurrent glioblastoma
Timothy Cloughesy, MD
|
| 6.55 PM |
|
Interactive clinical scenario discussion: Treatment considerations for a patient with recurrent glioblastoma
Moderator: Michael Prados, MD
Panelists: Timothy Cloughesy, MD; Minesh P. Mehta, MD; Wolfgang Wick, MD, PhD
|
| 7.10 PM |
|
Concluding remarks
Michael Prados, MD
|
| 7.15 PM |
|
Adjourn |
|
Faculty | Michael Prados, MD (Chair)
University of California, San Francisco
San Francisco, California, United States
Timothy Cloughesy, MD
University of California, Los Angeles
Los Angeles, California, United States
Minesh P. Mehta, MD
Northwestern University
Feinberg School of Medicine
Chicago, Illinois, United States
Wolfgang Wick, MD, PhD
University of Heidelberg and German Cancer Research Center
Heidelberg, Germany |
Target Audience | This educational activity is intended specifically for medical oncologists, neurologists, surgeons, and other healthcare professionals involved and/or interested in the management of patients with glioblastoma. |
Educational Objectives | Upon completion of this educational activity, participants should be able to:
- Discuss the classification, pathophysiology, and current role of biomarkers for glioblastoma.
- Review current standards of care for newly diagnosed and recurrent glioblastoma, including patient selection strategies and optimization of chemotherapy regimens.
- Compare and contrast the safety and efficacy of targeted therapies for treatment of glioblastoma and identify the molecular basis for their use.
|
Disclosure of Conflicts of Interest | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
Disclosure of Unlabeled Use of Agents | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Location | Hyatt Regency Orange County
11999 Harbor Boulevard
Garden Grove, CA 92840
714.750.1234 |
Sponsorship | This activity is sponsored by prIME Oncology.
 |
Continuing Education Statement |
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Support | Support for this activity has been provided by an unrestricted educational grant from:
 |
Statement | The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program. |
|
